Initial studies of trastuzamab, a monoclonal antibody binding to HER2, alone in HER2 lung cancer (measured HER2 expression by IHC) were disappointing, but the combination with chemotherapy appeared more promising [57,58,59] (Figure 1). The gene discussed is ERBB2; the disease is lung carcinoma.